Dasiglucagon is a glucagon analog. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Dasiglucagon has an FDA-approved product on the U.S. market, marketed as Zegalogue under application NDA214231.
The current label is held by Novo Nordisk.
From the FDA label
® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.Quoted from the FDA-approved prescribing information
The evidence
One source on Dasiglucagon, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Dasiglucagon's FDA-approved label indicates it for glycemic control or for a glucose emergency. These are the markers clinicians use when assessing blood sugar and insulin. They are listed here so you can read about them, not as a statement that Dasiglucagon changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Dasiglucagon. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides